Target intelligence / Profile preview

Gangliotetraosylceramide (Asialo-GM1) (GA1)

Target
GA1
Molecular classification
Glycolipid, Ganglioside, Neutral glycosphingolipid
01

Overview

Asialo-GM1, chemically known as gangliotetraosylceramide or GA1, is a neutral glycosphingolipid and a member of the ganglioside family that lacks the sialic acid residues found in GM1. It is predominantly expressed on the cell surface of natural killer (NK) cells, certain subsets of T lymphocytes, basophils, and fetal thymocytes, where it serves as a distinctive immunological marker [5]. In the central and peripheral nervous systems, it is localized in myelin and is involved in modulating neuronal plasticity, repair mechanisms, and the release of neurotrophins [1, 3]. Asialo-GM1 plays a significant role in human disease as a primary receptor for bacterial toxins, such as those produced by Cholera and E. coli, and as an adhesion site for pathogens like Pseudomonas aeruginosa [1]. It is also a critical target for pathogenic autoantibodies in various autoimmune peripheral neuropathies, including multifocal motor neuropathy and Guillain-Barré syndrome [6, 9]. In pharmacological and immunological research, anti-asialo-GM1 antibodies are standard tools used to selectively deplete NK cell populations in vivo to investigate their role in tumor surveillance and infectious disease models [5].

Other names
Asialo-GM1Asialo-GM1 gangliosideGA1Ganglio-N-tetraosylceramideGgOse4CerNeutral glycosphingolipid
02

Mechanism of action

Targeted depletion of natural killer (NK) cells and certain T cells via antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated lysis; competitive binding site for bacterial toxins and pathogen adhesins.

03

Biological functions

Cell surface markerImmune cell identificationLipid raft organizationPathogen receptorNeuronal plasticityAccessory molecule for T-cell receptors
04

Disease associations

InfectionMultifocal motor neuropathyGuillain-Barré syndromeMiller Fisher syndromeChronic inflammatory demyelinating polyneuropathyCancer
05

Safety considerations

Immunosuppression following NK cell depletionAutoantibody-mediated peripheral nerve damage (neuropathy)Cross-reactivity with other gangliosides during immunotherapy
06

Interacting drugs

Anti-asialo-GM1 antibody

2 more in the full profile.

07

Biomarkers

Anti-asialo-GM1 antibody titers (IgG/IgM)Natural killer (NK) cell count

Beyond the preview

Go deeper on Gangliotetraosylceramide (Asialo-GM1) (GA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gangliotetraosylceramide (Asialo-GM1) (GA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call